PNT2258: Phase I started

ProNAi began a single-arm, open-label, dose-escalation, U.S. Phase I trial to evaluate daily IV PNT2258 for the first 5 days of a 21-day cycle in 20 patients with advanced solid tumors. ProNAi has an ...